Guard Therapeutics International AB (publ) (GUARD.ST)
SEK 16.7
(0.6%)
SEK 16.7
(0.6%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -83.74 Million SEK | 58.34% |
| 2022 | -201 Million SEK | -6.58% |
| 2021 | -188.6 Million SEK | -109.46% |
| 2020 | -90.04 Million SEK | -67.43% |
| 2019 | -53.78 Million SEK | -285.27% |
| 2018 | -13.95 Million SEK | -83.38% |
| 2017 | -7.61 Million SEK | -8.6% |
| 2016 | -7 Million SEK | 62.72% |
| 2015 | -18.8 Million SEK | -354.62% |
| 2014 | -4.13 Million SEK | -139.84% |
| 2013 | 10.38 Million SEK | 553.16% |
| 2012 | -2.29 Million SEK | -432.69% |
| 2011 | -430.08 Thousand SEK | -162.61% |
| 2010 | -163.77 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -91.58 Million SEK | -40.72% |
| 2024 Q1 | -65.08 Million SEK | 22.28% |
| 2023 Q1 | -165.38 Million SEK | 17.72% |
| 2023 Q4 | -83.74 Million SEK | 18.85% |
| 2023 FY | -83.74 Million SEK | 58.34% |
| 2023 Q3 | -103.19 Million SEK | 19.54% |
| 2023 Q2 | -128.25 Million SEK | 22.45% |
| 2022 Q3 | -122.17 Million SEK | 19.27% |
| 2022 FY | -201 Million SEK | -6.58% |
| 2022 Q2 | -151.33 Million SEK | 11.63% |
| 2022 Q4 | -201 Million SEK | -64.53% |
| 2022 Q1 | -171.26 Million SEK | 9.17% |
| 2021 FY | -188.6 Million SEK | -109.46% |
| 2021 Q1 | -80.41 Million SEK | 10.69% |
| 2021 Q4 | -188.55 Million SEK | -424.96% |
| 2021 Q3 | -35.91 Million SEK | 46.34% |
| 2021 Q2 | -66.93 Million SEK | 16.76% |
| 2020 Q4 | -90.04 Million SEK | -246.44% |
| 2020 FY | -90.04 Million SEK | -67.43% |
| 2020 Q2 | -37.01 Million SEK | 20.61% |
| 2020 Q3 | -25.99 Million SEK | 29.79% |
| 2020 Q1 | -46.62 Million SEK | 13.3% |
| 2019 Q1 | -39.25 Million SEK | -181.19% |
| 2019 Q4 | -53.78 Million SEK | -36.33% |
| 2019 Q3 | -39.44 Million SEK | 24.62% |
| 2019 FY | -53.78 Million SEK | -285.27% |
| 2019 Q2 | -52.33 Million SEK | -33.33% |
| 2018 Q1 | -4.33 Million SEK | 43.12% |
| 2018 FY | -13.95 Million SEK | -83.38% |
| 2018 Q4 | -13.95 Million SEK | 3.7% |
| 2018 Q3 | -14.49 Million SEK | 46.98% |
| 2018 Q2 | -27.33 Million SEK | -531.39% |
| 2017 Q2 | -33.2 Million SEK | -1636.66% |
| 2017 Q4 | -7.61 Million SEK | 57.67% |
| 2017 FY | -7.61 Million SEK | -8.6% |
| 2017 Q3 | -17.98 Million SEK | 45.85% |
| 2017 Q1 | -1.91 Million SEK | 72.72% |
| 2016 Q3 | -26.54 Million SEK | 31.88% |
| 2016 Q2 | -38.96 Million SEK | -302.45% |
| 2016 Q1 | -9.68 Million SEK | 48.51% |
| 2016 FY | -7 Million SEK | 62.72% |
| 2016 Q4 | -7 Million SEK | 73.59% |
| 2015 FY | -18.8 Million SEK | -354.62% |
| 2015 Q2 | -22.98 Million SEK | -49873.91% |
| 2015 Q4 | -18.8 Million SEK | -60.68% |
| 2015 Q3 | -11.7 Million SEK | 49.1% |
| 2015 Q1 | -46 Thousand SEK | 98.89% |
| 2014 Q1 | 12.43 Million SEK | 19.8% |
| 2014 Q4 | -4.13 Million SEK | 54.71% |
| 2014 FY | -4.13 Million SEK | -139.84% |
| 2014 Q3 | -9.13 Million SEK | 29.99% |
| 2014 Q2 | -13.04 Million SEK | -204.88% |
| 2013 Q2 | 3.12 Million SEK | 671067.74% |
| 2013 Q1 | -465.00 SEK | 99.98% |
| 2013 Q3 | 7.89 Million SEK | 153.17% |
| 2013 Q4 | 10.38 Million SEK | 31.43% |
| 2013 FY | 10.38 Million SEK | 553.16% |
| 2012 FY | -2.29 Million SEK | -432.69% |
| 2012 Q4 | -2.29 Million SEK | 0.0% |
| 2011 FY | -430.08 Thousand SEK | -162.61% |
| 2010 FY | -163.77 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| NextCell Pharma AB | -46.79 Million SEK | -78.97% |
| Biovica International AB (publ) | -58.73 Million SEK | -42.569% |
| Abliva AB (publ) | -57.24 Million SEK | -46.298% |
| Active Biotech AB (publ) | -33.2 Million SEK | -152.232% |
| Aptahem AB (publ) | 2.9 Million SEK | 2979.041% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -67.412% |
| BioInvent International AB (publ) | -236.3 Million SEK | 64.562% |
| BioArctic AB (publ) | -606.58 Million SEK | 86.195% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -112.638% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1650.759% |
| Cantargia AB (publ) | -139.74 Million SEK | 40.077% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -8972.698% |
| CombiGene AB (publ) | -101.44 Million SEK | 17.448% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 56.99% |
| Fluicell AB (publ) | -2.76 Million SEK | -2930.8% |
| Genovis AB (publ.) | -43.94 Million SEK | -90.576% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 162.165% |
| Mendus AB (publ) | -96.29 Million SEK | 13.036% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -1.872% |
| LIDDS AB (publ) | -13.51 Million SEK | -519.753% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 508.294% |
| Saniona AB (publ) | 40.44 Million SEK | 307.039% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -85.198% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -67.703% |
| Xintela AB (publ) | -7.8 Million SEK | -972.365% |
| Amniotics AB (publ) | -5.63 Million SEK | -1386.879% |
| Corline Biomedical AB | -17.01 Million SEK | -392.247% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -184.998% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 74.552% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 0.002% |
| Intervacc AB (publ) | -88.16 Million SEK | 5.012% |
| Kancera AB (publ) | -45.69 Million SEK | -83.273% |
| Lipum AB (publ) | -8.46 Million SEK | -889.262% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -162.289% |
| Nanologica AB (publ) | -9.38 Million SEK | -792.0% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 74.899% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 150.423% |
| AcouSort AB (publ) | -23.98 Million SEK | -249.124% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -2.016% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -49.843% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 257.34% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -339.355% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 35.333% |
| Simris Alg AB (publ) | 85.07 Million SEK | 198.432% |
| Ziccum AB (publ) | -2.13 Million SEK | -3818.624% |
| SynAct Pharma AB | -61.75 Million SEK | -35.595% |
| OncoZenge AB (publ) | -12.62 Million SEK | -563.19% |
| Camurus AB (publ) | -1.16 Billion SEK | 92.814% |
| 2cureX AB (publ) | -13.4 Million SEK | -524.793% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -3775.104% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 39.383% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -533.002% |
| I-Tech AB | -83.26 Million SEK | -0.575% |
| Cyxone AB (publ) | -16.67 Million SEK | -402.346% |
| Biosergen AB | -1.88 Million SEK | -4347.212% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -291.039% |
| Alzinova AB (publ) | -21.22 Million SEK | -294.521% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -25.136% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1516.335% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -302.736% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -2717.665% |